Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

#4485

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Aim(s): To assess the incidence and outcomes of pts requiring hospital admission for hormone secretion within 14 days following LuTate therapy at our centre. Outcomes measured were elective versus unplanned admissions, length of stay, clinical or biochemical evidence of worsening hormone secretory syndrome and level of care required.

Materials and methods: A retrospective review of NEN patients treated with LuTate from March 2020 to Oct 2024 was conducted. Before treatment, all patients were assessed by the Nuclear Medicine team for risk factors of flare, discussed at a Multi-Disciplinary Meeting to determine elective admission needs, and had medical optimisation pre-admission, if required.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,